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Abstract
Objectives: Previous work from this group has demonstrated that melatonin (MLT) is capable of
signi icantly altering the growth and viability of oral cancer cell lines. The objective of this study was
to explore the receptors that may modulate MLT effects in oral cancers.
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Methods: Polymerase Chain Reaction (PCR) primers speci ic for the primary, cell-surface MLT
receptors (MT1 & MT2) were obtained and used to analyze the mRNA expression in CAL27, SCC15
and SCC25 oral cancer cell lines. Extracted RNA following MLT administration was also analyzed.
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Results: Expression of the primary MLT receptor MT1 was absent in all cell lines, although expression
of the secondary receptor (MT2) was observed. MLT administration within the physiologic range was
suf icient to induce MT1 expression in all cell lines, suggesting the MT2 receptor may initially
facilitate this process. Saturation of both MT1 and MT2 receptors observed within the
supraphysiologic ranges correlated with the induction of apoptosis-related caspase signaling and the
activation of the intranuclear MLT receptor RZR.
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Conclusions: This may be the irst study to demonstrate the down-regulation of MT1 mRNA in oral
cancers, as well as novel evidence of the speci ic role of melatonin and the cognate receptors in
modulating oral cancer growth.
Keywords: Oral Cancer; Melatonin.

Introduction
Melatonin (MLT) is a hormone largely produced by the pineal gland in regular daily cycles in most
mammals and humans, in particular [1]. Although melatonin may be intricately involved in the
regulation of many diverse physiological processes, the most widely recognized and frequently
studied is the role of MLT in the regulation of the sleep-wake cycle [2]. Although epidemiologic
evidence has suggested that disruption of the sleep-wake cycle, frequently encountered with shift
https://bioaccent.org/cancer-sciences/cancer-sciences03.php
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workers, may be linked with MLT dysregulation and increased risk for some cancers–more recent
evidence has suggested that melatonin has more speci ic physiologic and pathologic functions speci ic
to the oral cavity [3-5].
For example, recent studies have suggested melatonin and disruption of melatonin-speci ic pathways
may be a critically important factor that increases risk of oral disorders, and more speci ically for oral
cancer [6]. In addition, new evidence has suggested that silencing and down-regulation of melatonin
receptors may, in fact, be a common feature of many oral cancers [7-9]. Recent studies from this group
have now demonstrated that administration of melatonin at physiologically-relevant concentrations
can inhibit the growth of oral cancers in vitro, although these studies did not evaluate any effects on
melatonin receptors, such as silencing or down-regulation [10].
On the basis of this information, the primary objective of the current study involved the examination
of the expression of the cell-surface, membrane-bound melatonin receptors MT1 and MT2, as well as
the intracellular receptor RZR in oral cancer cell lines. In addition, the experimental administration of
melatonin at physiologic and supraphysiologic (supplementation equivalent) concentrations were
evaluated with the speci ic aim of analyzing changes to MT1, MT2 and RZR expression to correlate
with the observed changes to cellular behavior.

Materials and Methods
Cell culture and cell lines
The human oral squamous cell carcinoma lines, SCC15 (CRL-1623), SCC25 (CRL-1628), and CAL27
(CRL-2095) were obtained from American Type Culture Collection (ATCC: Manassas, VA). CAL27 cells
were maintained in Dulbecco’s Modi ied Eagle’s Medium (DMEM) with 4.0 mM L-Glutamine adjusted
to contain 3.7 g/L sodium bicarbonate, 4.5 g/L glucose, and 110 mg/L sodium pyruvate, obtained
from HyClone (Logan, UT). SCC15 and SCC25 cells were maintained in a 1:1 mixture of DMEM and
Ham’s F12 medium obtained from HyClone (Logan UT) with 2.5 mM L-Glutamine, modi ied to contain
15 mM 4-2-hydroxyethyl-1-piperazineethanesulfonic acid (HEPES), 0.5 mM sodium pyruvate, and 1.2
g/L sodium bicarbonate. All cell culture media was supplemented with 1% Penicillin (10,000
units/mL)-Streptomycin (10,000 ug/mL) solution and 10% fetal bovine serum (FBS) obtained from
HyClone (Logan, UT). Cells were cultured in 75 cm2 BD Falcon tissue-culture treated lasks (Bedford,
MA) at 37°C and 5% CO2 in humidi ied chambers.
Materials
Melatonin (N-acetyl-5-methoxy-tryptamine, MLT) was obtained from GNC Preventive Nutrition®
(Pittsburgh, PA). Cellular assays were performed in the appropriate complete media, with and
without the addition of MLT (10, 50 and 100 pg/mL). This concentration range approximates normal
human physiologic serum concentrations (10.6 ± 1.7 – 94.8 ± 22.6 pg/mL) [11,12]. In addition,
supraphysiologic concentrations of MLT were also utilized, to approximate serum and saliva
concentrations of melatonin administered as an over-the-counter supplement (0.2 – 10 ug/mL)
[11,12].
Proliferation
Proliferation assays were performed in the appropriate complete media, with and without the
addition of MLT, prior to the start of each experimental assay. In brief, cells were plated in Corning
Costar high-throughput, lat bottom, tissue culture-treated 96-well assay plates (Corning, NY) at a
concentration of 1.2 x 105 cells per well, which roughly approximates 30-40% con luence per well at
the onset of each assay. Proliferation was subsequently measured after three days. In brief, cultured
cells were ixed after 72 hours, or day 3 (d3), using 50 uL of 10% buffered formalin for 24 hours at
room temperature, and were subsequently processed as follows: liquid media (containing formalin)
was aspirated in a chemical fume hood, cells were subsequently stained using 50 uL of crystal violet
1% aqueous solution (Fisher Scienti ic: Fair Lawn, NJ) for 20 minutes at room temperature. The stain
was then aspirated and wells were then washed with 100 uL of 1X phosphate-buffered saline (PBS)
solution for one (1) minute, followed by aspiration. The relative absorbance of each well was then
measured at 630 nm using a Bio-Tek ELx808 microplate reader (Winooski, VT). The change in
proliferation, measured as the change in absorbance between day 3 and day 1 (d3-d1) was calculated
and compared with baseline controls (cells receiving media with no melatonin). The data were
analyzed and graphed using Microsoft Excel (Redmond, WA) and SPSS (Chicago, IL). Three separate,
independent replications of each experimental condition (physiologic, supraphysiologic) were
performed on each cell line by the study authors in random order over the course of three
consecutive weeks.
RT-PCR: Melatonin receptor expression
https://bioaccent.org/cancer-sciences/cancer-sciences03.php
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To determine whether the observed effects of melatonin on proliferation or viability were associated
with changes to MT1, MT2 or RZR expression, RNA was isolated from 1.5 × 107 cells from all cell lines
at 72 hours after growth inhibitory maximum (GIMAX) MLT administration from both the physiologic
and supraphysiologic range (100 pg/mL and 10 mg/mL) using ABgene Total RNA Isolation Reagent
(Epsom, Surrey,UK) and the procedure recommended by the manufacturer [10]. RT-PCR was
performed with the ABgene Reverse-iT One-Step RT-PCR Kit (ReadyMix Version) and a Mastercycler
gradient thermocycler (Eppendorf: Hamburg, Germany). The following primers for MT1, MT2 and
RZR, were synthesized by SeqWright (Houston, TX) [13,14]:
MT1 forward primer, TGGCATATAGGTTGCAGTCTCGG;
MT1 reverse primer, TGTTCTGTAGGCTTGGGCAGTTG;
MT2 forward primer, ACATGGAAGCGAATCAATGGACTC;
MT2 reverse primer, AAGGACTCAAATTCTGTTGCCACC;
RZR forward primer, GATATTGGGGAACAACTGGAC;
RZR reverse primer, CATGTCATCATCCAGTTTGCA;

In brief, one µg of template (total) RNA was used for each reaction. The reverse transcription step ran
for 30 minutes at 47°C, followed by denaturation for 2 minutes at 94°C. Thirty ive ampli ication
cycles were run, consisting of 20 second denaturation at 94°C, 30 seconds of annealing at 58°C, and
6.5 minutes of extension at 72°C. Final extension was run for 5 minutes at 72°C. Reaction products
were separated by gel electrophoresis using Reliant 4% NuSieve R3:1 Plus Agarose gels (Lonza:
Rockland, ME). Bands were visualized by UV illumination of ethidium-bromide-stained gels and
captured using a Kodak Gel Logic 100 Imaging System and 1D Image Analysis Software (Eastman
Kodak: Rochester, NY). Quanti ication of RT-PCR band densitometry was performed using Adobe (San
Jose, CA) Photoshop imaging software, Image Analysis tools.

Results and Discussion
Growth of SCC25, SCC15 and CAL27 oral cancer cell lines, with and without the addition of MLT, was
assessed for comparison with the expression of MT1, MT2 and RZR (Figure 1). More speci ically, the
control cells (no MLT) increased in number by approximately one third (31.5%, 33.2% and 39.1%,
respectively) (Fig. 1A). An assessment by RT-PCR from extracted RNA revealed the absence of MT1
mRNA in all three cell lines, although mRNA speci ic for MT2 was observed (Fig. 1B).
The administration of MLT at the previously determined growth inhibitory maximum (GIMAX) of 100
pg/mL within the normal physiologic range (Phys) was suf icient to inhibit SCC25 growth by -16.1%,
SCC15 y -36.5%, and CAL27 by 43.1% (Fig. 1C). Furthermore, the addition of MLT at this physiologic
concentration was associated with a slight up-regulation of MT2 mRNA expression, as well as the
introduction of MT1 mRNA expression (Fig. 1D).
Administration of MLT at concentrations that approximate the GIMAX for the supraphysiologic dose
(Supr) observed among those taking oral supplements also inhibited SCC25 (-42.9%), SCC15
(-58.2%) and CAL27 (-71.3%) growth (Fig. 1E).

Farnoush et al. Figure 1. Growth of SCC25, SCC15 and CAL27 oral cancer cell lines, with and without
the addition of MLT in both physiologic (Phys) and supraphysiologic (Supr) concentrations using cell
surface, membrane-bound receptors MT1 and MT2.
A marked up-regulation in both MT1 and MT2 mRNA expression was also observed (Fig. 1F). This
increase ranged between 15-fold (CAL27: MT1; SCC25: MT2) and 30-fold (SCC25: MT1; CAL27: MT2).
As MLT is an amphipathic hormone that possesses the ability to bind both cell surface as well as
intracellular receptors, the expression of the intracellular receptor RZR was also assessed (Figure 2).
https://bioaccent.org/cancer-sciences/cancer-sciences03.php
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Figure 2. Expression of the intracellular receptor RZR using SCC25, SCC15 and CAL27 oral cancer cell
lines, with and without the addition of MLT in both physiologic (Phys) and supraphysiologic (Supr)
GIMAX concentrations.
These analyses revealed that RZR is not actively transcribed in either SCC25 or CAL27 cells under
MLT-free conditions, although expression in SCC15 cells was noted (Fig. 2A). Administration of MLT at
physiologically relevant concentrations induced expression of RZR in CAL27 cells but not SCC25 cells,
while SCC15 expression was slightly down-regulated. However, supraphysiologic concentrations of
MLT were the only concentration tested that induced RZR expression in SCC25 cells. Moreover, RZR
expression in both SCC15 and CAL27 cells was substantially increased.
As previous studies from this group demonstrated that only supraphysiologic concentrations of MLT
induced the expression of key apoptosis regulatory genes, Caspase-2 and Caspase-3, the relative
expression of the intracellular RZR receptor, graphed on the X-axis, was plotted against the expression
of these apoptosis-speci ic products on the Y-axis for comparison (Fig. 2B). These analyses revealed
that the relative abundance of RZR mRNA transcription was strongly associated with activation of
Caspase-2 and Caspase-3 expression in all three cell lines (R=0.731).
When combined, these data strongly suggest an interconnected and complex relationship between
MLT administration and MLT receptor activation (Figure 3). For example, MT1 expression appears to
be suppressed in these oral cancer cell lines, although MT2 expression was still observed.
Administration of MLT within the normal physiologic concentration was suf icient to induce an upregulation of MT2 expression, while MT1 expression appeared to be rescued. In addition, the
apparent saturation of both MT2 and MT1 receptors with the supraphysiologic concentration was
suf icient to allow consequent membrane crossing and direct intracellular transport of MLT to bind
with and up-regulate expression of the RZR receptor. Finally, this activation of RZR appears to be
suf icient to induce expression of apoptosis-speci ic regulators Caspase-2 and Caspase-3, which also
appeared to exhibit expression strongly correlated with RZR expression. concentrations associated
with supraphysiolgic dosages. This activation of RZR appeared to be strongly correlated with
activation of the apoptosis-speci ic Caspase initiation pathway (Caspase-2, Caspase-3). This may
suggest that only concentrations of MLT commensurate with supplementation are suf icient to
saturate the

https://bioaccent.org/cancer-sciences/cancer-sciences03.php
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Conclusions
The primary purpose of this study was to explore the expression of the membrane-associated MLT
receptors MT1 and MT2, as well as the intracellular receptor RZR in the context of previous results
that suggested MLT administration at physiologic and supraphysiologic concentrations was suf icient
to inhibit growth of oral cancer cell lines [10]. The main indings of this project suggest that
expression of at least one MLT receptor, MT1, was suppressed in all three cell lines – although MT2
expression remained intact. Moreover, the effects of MLT administration appeared to function through
the MT2 receptor, as the physiologic dose of MLT was suf icient to up-regulate expression of MT2, as
well as to induce expression of MT1. This may suggest that transcriptional suppression of MT1
expression may not only be reversible but may also be dependent upon the activation of MT2 through
its activation by MLT.
Interestingly, expression of the intracellular receptor RZR did not appear to be activated by
physiologically relevant concentrations of MLT, but were signi icantly up-regulated by the super
saturation cell surface receptors in order to facilitate the cross-membrane passage of MLT to directly
activate the intracellular RZR receptor.
These phenomena are consist with other similar biphasic effects observed in other studies of MLT
demonstrating that only the saturation of cell surface MLT receptors allowed excess MLT to move
along the concentration gradient directly into the cell, subsequently binding the alternative
intracellular ligands [15-17]. However, these results also appear to con irm previous observations
that although apoptosis may be induced only at the supraphysiologic supplementation
concentrations, even the lowest concentrations of physiologically relevant concentrations were
suf icient to activate MT2 expression and to recover MT1 expression in all cell lines evaluated.
Although a number of clinical, biomedical and epidemiologic investigations have provided evidence
that MLT may have signi icant effects on oral cancer risk, progression and even mortality, this study
provides novel information about the receptors and associated mechanisms that may be involved in
the cellular response of oral cancers to MLT administration. This study may the irst to demonstrate
that MT1 expression, lost in many oral cancers, may be recovered with MLT administration, an effect
that could prove useful for complementary and alternative therapies for oral cancer. Finally, this study
provided initial data to suggest that the induction of apoptosis following supraphysiologic MLT
administration may be correlated with RZR expression, suggesting that this pathway may be an
important and critical interlocutor that functions to activate these pathways in at least these oral
cancer lines. Future studies that investigate these receptors, pathways and the mechanisms involved
in their control may prove indispensible to oral health researchers and oncologists who search for
new methods to control or inhibit the growth and spread of oral cancers.
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